The study's authors tracked data from more than 2 million women.

There are approximately 20,000 proteins in the human heart—and one of them, if administered as a drug, could help patients recover more quickly following a myocardial infarction.

Researchers have found a link between myocardial injury and a higher risk of death among patients hospitalized in the United States for COVID-19.

So what, exactly, occurs inside the human heart during a myocardial infarction?

Verve Therapeutics, a healthcare company focused on improving cardiovascular outcomes through gene-editing technology, has raised $63 million in Series A2 financing.

Hospitals throughout the United States have reported that a general fear of COVID-19 has led to significant drops in patients presenting with heart attack symptoms and other cardiovascular issues.

Ticagrelor has been approved by the FDA for reducing the risk of a first heart attack or stroke in high-risk coronary artery disease (CAD) patients.

Evolocumab is an effective treatment option for patients with a recent myocardial infarction (MI), according to new findings published in JAMA Cardiology.

The first known death from COVID-19 in the United States was caused by a ventricular rupture.  

Women are prescribed fewer drugs after a heart attack than men—and they are more likely to die afterward as a result of that disparity.

Women in rural parts of the United States have experienced an increase in premature coronary artery disease (CAD) mortality, according to new findings published in the Journal of the American Heart Association.

The COVID-19 pandemic has changed patient care in countless ways, but percutaneous coronary intervention (PCI) remains the recommended standard of care for ST-segment elevation myocardial infarction (STEMI) patients.